Immatics
is a Germany-based clinical-stage biopharmaceutical company that researches and develops T-cell immunotherapies for the treatment of cancer... Read moreImmatics
is a Germany-based clinical-stage biopharmaceutical company that researches and develops T-cell immunotherapies for the treatment of cancer... Read more
News
Mar 28, 2025
Seeking Alpha
Immatics: Immatics N.V.: Trading Below Cash, But Not Without Reason
Mar 27, 2025
Marketscreener
Immatics: Immatics Announces Full Year 2024 Financial Results and Business Update
Mar 27, 2025
Seeking Alpha
Immatics: Immatics GAAP EPS of 0.14 beats, revenue of $161.9M
Jan 15, 2025
Zacks
Immatics: Down -16.85% in 4 Weeks, Here's Why Immatics (IMTX) Looks Ripe for a Turnaround
Nov 18, 2024
Marketscreener
Immatics: Immatics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Nov 18, 2024
Yahoo
Immatics: Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER IMA402 Targeting PRAME
Nov 08, 2024
FinanzNachrichten
Immatics: Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Oct 11, 2024
Seeking Alpha
Immatics: Immatics prices $150M equity offering
Oct 10, 2024
Endpoints News
Immatics: Immatics heads to Phase 3 with melanoma cell therapy, seeks to raise $150M
Sep 16, 2024
Endpoints News
Immatics: Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager
Immatics Competitors
1
2
3
4
5
6
7
8
9
10